Jailendra Singh
Stock Analyst at Truist Securities
(0.83)
# 3,997
Out of 5,161 analysts
193
Total ratings
24.77%
Success rate
-26.13%
Average return
Main Sectors:
Stocks Rated by Jailendra Singh
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VEEV Veeva Systems | Reiterates: Buy | $275 → $262 | $180.79 | +44.92% | 8 | Mar 5, 2026 | |
| PGNY Progyny | Maintains: Buy | $34 → $28 | $17.50 | +60.00% | 11 | Mar 2, 2026 | |
| PRVA Privia Health Group | Maintains: Buy | $31 → $33 | $21.73 | +51.86% | 9 | Mar 2, 2026 | |
| EVH Evolent Health | Maintains: Buy | $10 → $6 | $3.06 | +96.08% | 9 | Feb 26, 2026 | |
| HIMS Hims & Hers Health | Reiterates: Hold | $37 → $18 | $23.84 | -24.50% | 12 | Feb 24, 2026 | |
| IQV IQVIA Holdings | Maintains: Buy | $290 → $245 | $162.93 | +50.37% | 19 | Feb 19, 2026 | |
| WAY Waystar Holding | Maintains: Buy | $51 → $38 | $24.61 | +54.41% | 4 | Feb 18, 2026 | |
| MEDP Medpace Holdings | Maintains: Hold | $555 → $539 | $443.85 | +21.44% | 7 | Feb 11, 2026 | |
| DOCS Doximity | Maintains: Buy | $62 → $37 | $24.28 | +52.39% | 10 | Feb 6, 2026 | |
| MDLN Medline | Initiates: Buy | $52 | $41.07 | +26.61% | 1 | Jan 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $231 → $222 | $97.45 | +127.81% | 11 | Jan 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $12 → $22 | $9.07 | +142.69% | 1 | Jan 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $35 → $36 | $11.00 | +227.27% | 7 | Sep 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $48 | $44.46 | +7.96% | 1 | Jun 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $10 → $9 | $5.36 | +67.91% | 16 | May 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $6.5 → $5.5 | $2.21 | +148.87% | 12 | Apr 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $12 → $7.5 | $5.49 | +36.61% | 7 | Apr 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $50 → $46 | $23.25 | +97.85% | 5 | Mar 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $17 → $14 | $10.75 | +30.23% | 1 | Jul 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $6.4 → $6.5 | $0.60 | +974.56% | 8 | May 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $16 → $13 | $1.51 | +760.93% | 11 | May 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $30 → $24 | $1.13 | +2,023.89% | 2 | Feb 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $14 → $4 | $0.65 | +513.31% | 4 | Feb 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $60 → $58 | $219.09 | -73.53% | 2 | Feb 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $90 → $45 | $1.66 | +2,610.84% | 7 | Jan 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $230 → $333 | $944.36 | -64.74% | 6 | Jan 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $10 → $9 | $1.97 | +356.85% | 2 | May 19, 2021 |
Veeva Systems
Mar 5, 2026
Reiterates: Buy
Price Target: $275 → $262
Current: $180.79
Upside: +44.92%
Progyny
Mar 2, 2026
Maintains: Buy
Price Target: $34 → $28
Current: $17.50
Upside: +60.00%
Privia Health Group
Mar 2, 2026
Maintains: Buy
Price Target: $31 → $33
Current: $21.73
Upside: +51.86%
Evolent Health
Feb 26, 2026
Maintains: Buy
Price Target: $10 → $6
Current: $3.06
Upside: +96.08%
Hims & Hers Health
Feb 24, 2026
Reiterates: Hold
Price Target: $37 → $18
Current: $23.84
Upside: -24.50%
IQVIA Holdings
Feb 19, 2026
Maintains: Buy
Price Target: $290 → $245
Current: $162.93
Upside: +50.37%
Waystar Holding
Feb 18, 2026
Maintains: Buy
Price Target: $51 → $38
Current: $24.61
Upside: +54.41%
Medpace Holdings
Feb 11, 2026
Maintains: Hold
Price Target: $555 → $539
Current: $443.85
Upside: +21.44%
Doximity
Feb 6, 2026
Maintains: Buy
Price Target: $62 → $37
Current: $24.28
Upside: +52.39%
Medline
Jan 12, 2026
Initiates: Buy
Price Target: $52
Current: $41.07
Upside: +26.61%
Jan 8, 2026
Downgrades: Hold
Price Target: $231 → $222
Current: $97.45
Upside: +127.81%
Jan 8, 2026
Upgrades: Buy
Price Target: $12 → $22
Current: $9.07
Upside: +142.69%
Sep 8, 2025
Maintains: Buy
Price Target: $35 → $36
Current: $11.00
Upside: +227.27%
Jun 16, 2025
Initiates: Buy
Price Target: $48
Current: $44.46
Upside: +7.96%
May 27, 2025
Maintains: Hold
Price Target: $10 → $9
Current: $5.36
Upside: +67.91%
Apr 10, 2025
Maintains: Hold
Price Target: $6.5 → $5.5
Current: $2.21
Upside: +148.87%
Apr 10, 2025
Maintains: Hold
Price Target: $12 → $7.5
Current: $5.49
Upside: +36.61%
Mar 18, 2025
Maintains: Buy
Price Target: $50 → $46
Current: $23.25
Upside: +97.85%
Jul 2, 2024
Maintains: Buy
Price Target: $17 → $14
Current: $10.75
Upside: +30.23%
May 24, 2024
Maintains: Hold
Price Target: $6.4 → $6.5
Current: $0.60
Upside: +974.56%
May 4, 2022
Maintains: Neutral
Price Target: $16 → $13
Current: $1.51
Upside: +760.93%
Feb 24, 2022
Maintains: Neutral
Price Target: $30 → $24
Current: $1.13
Upside: +2,023.89%
Feb 8, 2022
Downgrades: Neutral
Price Target: $14 → $4
Current: $0.65
Upside: +513.31%
Feb 4, 2022
Maintains: Neutral
Price Target: $60 → $58
Current: $219.09
Upside: -73.53%
Jan 7, 2022
Downgrades: Underperform
Price Target: $90 → $45
Current: $1.66
Upside: +2,610.84%
Jan 7, 2022
Upgrades: Outperform
Price Target: $230 → $333
Current: $944.36
Upside: -64.74%
May 19, 2021
Maintains: Neutral
Price Target: $10 → $9
Current: $1.97
Upside: +356.85%